Cancer Research and Treatment

Jae Ill Zo

11 Articles

Lung and Thoracic cancer

Psychometric Validation of the Korean Version of the Cancer Survivors’ Unmet Needs (CaSUN) Scale among Korean Non–Small Cell Lung Cancer Survivors: Danbee Kang, Genehee Lee, Sooyeon Kim, Heesu Nam, Sunga Kong, Sungkeun Shim, Jae Kyung Lee, Wonyoung Jung, Sumin Shin, Hong Kwan Kim, Jae Ill Zo, Young Mog Shim, Dong Wook Shin, Juhee Cho; Cancer Res Treat. 2023;55(1):61-72. Published online February 23, 2022; DOI: https://doi.org/10.4143/crt.2021.1583

Purpose
The purpose of the study was to validate the Korean version of Cancer Survivors’ Unmet Needs (CaSUN) scale among non–small cell lung cancer survivors.
Materials and Methods
Participants were recruited from outpatient clinics at the Samsung Medical Center in Seoul, South Korea, from January to October 2020. Participants completed a survey questionnaire that included the CaSUN. Exploratory and confirmatory factor analysis and Pearson’s correlations were used to evaluate the reliability and validity of the Korean version of the CaSUN (CaSUN-K). We also tested known-group validity using an independent t test or ANOVA.
Results
In total, 949 provided informed consent and all of which completed the questionnaire. Among the 949 patients, 529 (55.7%) were male; the mean age and median time since the end of active treatment (standard deviation) was 63.4±8.8 years and the median was 18 months. Although the factor loadings were different from those for the original scale, the Cronbach’s alpha coefficients of the six domains in the CaSUN-K ranged from 0.68 to 0.95, indicating satisfactory internal consistency. In the CFA, the goodness-of-fit indices for the CaSUN-K were high. Moderate correlations demonstrated the convergent validity of CaSUN-K with the relevant questionnaire. More than 60% of the participants reported information-related unmet needs, and the CaSUN-K discriminated between the needs reported by the different subgroups that we analyzed.
Conclusion
The CaSUN-K is a reliable and valid measure for assessing the unmet needs in a cancer population, thus this tool help population to receive timely, targeted, and relevant care.

Citations

Citations to this article as recorded by

Supporting Life Adjustment in Patients With Lung Cancer Through a Comprehensive Care Program: Protocol for a Controlled Before-and-After Trial
Wonyoung Jung, Alice Ahn, Genehee Lee, Sunga Kong, Danbee Kang, Dongok Lee, Tae Eun Kim, Young Mog Shim, Hong Kwan Kim, Jongho Cho, Juhee Cho, Dong Wook Shin
JMIR Research Protocols.2024; 13: e54707. CrossRef
Validity and Reliability of a Simplified Chinese Version of Cancer Survivors' Unmet Needs Scale (CaSUN)
Xiaojingyuan Xu, Xiaoyun Liang, Shiquan Yin
Psycho-Oncology.2024;[Epub] CrossRef
Unmet Supportive Care Needs after Non-Small Cell Lung Cancer Resection at a Tertiary Hospital in Seoul, South Korea
Junhee Park, Wonyoung Jung, Genehee Lee, Danbee Kang, Young Mog Shim, Hong Kwan Kim, Ansuk Jeong, Juhee Cho, Dong Wook Shin
Healthcare.2023; 11(14): 2012. CrossRef
Kanserden Kurtulanların Karşılanmayan İhtiyaçları Ölçeğinin Türkçeye Uyarlanması: Geçerlik ve Güvenirlik Çalışması
Gülyeter Erdoğan Yüce, Gamze Muz, Ayser Döner
Hacettepe Üniversitesi Hemşirelik Fakültesi Dergisi.2023; 10(3): 264. CrossRef
Psychometric properties of the Slovenian version of the Cancer Survivors’ Unmet Needs (CaSUN-SL) measure in post-treatment cancer survivors
Špela Miroševič, Polona Selič-Zupančič, Judith Prins, Vesna Homar, Zalika Klemenc-Ketiš
BMC Psychology.2022;[Epub] CrossRef

5,831 View
166 Download
4 Web of Science
5 Crossref

The Role of Adjuvant Therapy Following Surgical Resection of Small Cell Lung Cancer: A Multi-Center Study: Seong Yong Park, Samina Park, Geun Dong Lee, Hong Kwan Kim, Sehoon Choi, Hyeong Ryul Kim, Yong-Hee Kim, Dong Kwan Kim, Seung-Il Park, Tae Hee Hong, Yong Soo Choi, Jhingook Kim, Jong Ho Cho, Young Mog Shim, Jae Ill Zo, Kwon Joong Na, In Kyu Park, Chang Hyun Kang, Young-Tae Kim, Byung Jo Park, Chang Young Lee, Jin Gu Lee, Dae Joon Kim, Hyo Chae Paik; Cancer Res Treat. 2023;55(1):94-102. Published online June 9, 2022; DOI: https://doi.org/10.4143/crt.2022.290

Abstract PDF Supplementary Material PubReader ePub

Purpose
This multi-center, retrospective study was conducted to evaluate the long-term survival in patients who underwent surgical resection for small cell lung cancer (SCLC) and to identify the benefit of adjuvant therapy following surgery.
Materials and Methods
The data of 213 patients who underwent surgical resection for SCLC at four institutions were retrospectively reviewed. Patients who received neoadjuvant therapy or an incomplete resection were excluded.
Results
The mean patient age was 65.29±8.93 years, and 184 patients (86.4%) were male. Lobectomies and pneumonectomies were performed in 173 patients (81.2%), and 198 (93%) underwent systematic mediastinal lymph node dissections. Overall, 170 patients (79.8%) underwent adjuvant chemotherapy, 42 (19.7%) underwent radiotherapy to the mediastinum, and 23 (10.8%) underwent prophylactic cranial irradiation. The median follow-up period was 31.08 months (interquartile range, 13.79 to 64.52 months). The 5-year overall survival (OS) and disease-free survival were 53.4% and 46.9%, respectively. The 5-year OS significantly improved after adjuvant chemotherapy in all patients (57.4% vs. 40.3%, p=0.007), and the survival benefit of adjuvant chemotherapy was significant in patients with negative node pathology (70.8% vs. 39.7%, p=0.004). Adjuvant radiotherapy did not affect the 5-year OS (54.6% vs. 48.5%, p=0.458). Age (hazard ratio [HR], 1.032; p=0.017), node metastasis (HR, 2.190; p < 0.001), and adjuvant chemotherapy (HR, 0.558; p=0.019) were associated with OS.
Conclusion
Adjuvant chemotherapy after surgical resection in patients with SCLC improved the OS, though adjuvant radiotherapy to the mediastinum did not improve the survival or decrease the locoregional recurrence rate.

Citations

Citations to this article as recorded by

Application of postoperative adjuvant radiotherapy in limited-stage small cell lung cancer: A systematic review and meta-analysis
Chuanhao Zhang, Genghao Zhao, Huajian Wu, Jianing Jiang, Wenyue Duan, Zhijun Fan, Zhe Wang, Ruoyu Wang
Radiotherapy and Oncology.2024; 193: 110123. CrossRef
A 15-Gene-Based Risk Signature for Predicting Overall Survival in SCLC Patients Who Have Undergone Surgical Resection
Sevcan Atay
Cancers.2023; 15(21): 5219. CrossRef

5,569 View
138 Download
2 Web of Science
2 Crossref

Lung Cancer

Conditional Survival of Surgically Treated Patients with Lung Cancer: A Comprehensive Analyses of Overall, Recurrence-free, and Relative Survival: Dong Wook Shin, Jong Ho Cho, Jung Eun Yoo, Juhee Cho, Dong Woog Yoon, Genehee Lee, Sumin Shin, Hong Kwan Kim, Yong Soo Choi, Jhingook Kim, Jae Ill Zo, Young Mog Shim; Cancer Res Treat. 2021;53(4):1057-1071. Published online March 9, 2021; DOI: https://doi.org/10.4143/crt.2020.1308

Abstract PDF PubReader ePub

Purpose
Survival probability changes over time in cancer survivors. This study examined conditional survival in patients undergoing curative resection for non-small cell lung cancer (NSCLC).
Materials and Methods
Five-year conditional recurrence-free survival (CRFS), conditional overall survival (COS), and conditional relative survival (CRS) up to 10 years after surgery were calculated in patients who underwent NSCLC resection from 1994 to 2016. These rates were stratified according to age, sex, year of diagnosis, pathological stage, tumor histology, smoking status, comorbidity, and lung function.
Results
Five-year CRFS increased from 65.6% at baseline to 90.9% at 10 years after surgery. Early differences in 5-year CRFS according to stratified patient characteristics disappeared, except for age: older patients exhibited persistently lower 5-year CRFS. Five-year COS increased from 72.7% to 78.3% at 8 years and then decreased to 75.4% at 10 years. Five-year CRS increased from 79.0% at baseline to 86.8% at 10 years. Older age and higher pathologic stage were associated with lower 5-year COS and CRS up to 10 years after surgery. Female patients, those with adenocarcinoma histology, non-smokers, patient without comorbidities and had good lung function showed higher COS and CRS.
Conclusion
CRFS improved over time, but significant risk remained after 5 years. CRS slightly improved over time but did not reach 90%, suggesting significant excess mortality compared to the general population. Age and stage remained significant predictors of conditional survival several years after surgery. Our conditional survival estimates should help clinicians and patients make informed treatment and personal life decisions based on survivorship status.

Citations

Citations to this article as recorded by

COL3A1‐positive endothelial cells influence LUAD prognosis and regulate LUAD carcinogenesis by NCL–PI3K–AKT axis
Moyan Zhang, Yicheng Liang, Peng Song
The Journal of Gene Medicine.2024;[Epub] CrossRef
Adjustment to “new normal” after cancer among non–small cell lung cancer survivors: A qualitative study
Genehee Lee, Soo Yeon Kim, Alice Ahn, Sunga Kong, Heesu Nam, Danbee Kang, Hong Kwan Kim, Young Mog Shim, Ansuk Jeong, Dong Wook Shin, Juhee Cho
Palliative and Supportive Care.2024; 22(3): 487. CrossRef
Spatial features of specific CD103+CD8+ tissue-resident memory T cell subsets define the prognosis in patients with non-small cell lung cancer
Guanqun Yang, Siqi Cai, Mengyu Hu, Chaozhuo Li, Liying Yang, Wei Zhang, Jujie Sun, Fenghao Sun, Ligang Xing, Xiaorong Sun
Journal of Translational Medicine.2024;[Epub] CrossRef
Supporting Life Adjustment in Patients With Lung Cancer Through a Comprehensive Care Program: Protocol for a Controlled Before-and-After Trial
Wonyoung Jung, Alice Ahn, Genehee Lee, Sunga Kong, Danbee Kang, Dongok Lee, Tae Eun Kim, Young Mog Shim, Hong Kwan Kim, Jongho Cho, Juhee Cho, Dong Wook Shin
JMIR Research Protocols.2024; 13: e54707. CrossRef
Conditional Survival of Patients with Limited-Stage Small Cell Lung Cancer After Surgery: A National Real-World Cohort Study
Jun-Peng Lin, Xiao-Feng Chen, Peiyuan Wang, Hao He, Wei-Jie Chen, Feng-Nian Zhuang, Hang Zhou, Yu-Jie Chen, Wen-Wei Wei, Shuo-Yan Liu, Feng Wang
Annals of Surgical Oncology.2024; 31(7): 4250. CrossRef
Cost‐Effectiveness Analysis of Adjuvant Alectinib versus Platinum‐Based Chemotherapy in Resected ALK‐Positive Non‐Small‐Cell Lung Cancer in the Chinese Health Care System
Qiran Wei, Yifang Liang, Jiahui Mao, Xin Guan
Cancer Medicine.2024;[Epub] CrossRef
Dynamic evaluation of postoperative survival in intrahepatic cholangiocarcinoma patients who did not undergo lymphadenectomy: a multicenter study
Tingfeng Huang, Jie Kong, Hongzhi Liu, Zhipeng Lin, Qizhu Lin, Jianying Lou, Shuguo Zheng, Xinyu Bi, Jianming Wang, Wei Guo, Fuyu Li, Jian Wang, Yamin Zheng, Jingdong Li, Shi Cheng, Weiping Zhou, Yongyi Zeng
Scandinavian Journal of Gastroenterology.2023; 58(2): 178. CrossRef
A2aR on lung adenocarcinoma cells: A novel target for cancer therapy via recruiting and regulating tumor-associated macrophages
Ying Bai, Xin Zhang, Jiawei Zhou, Jianqiang Guo, Yafeng Liu, Chao Liang, Wenyang Wang, Yingru Xing, Jing Wu, Dong Hu
Chemico-Biological Interactions.2023; 382: 110543. CrossRef
Survival and Quality-of-life Outcomes in Early-Stage NSCLC Patients: a Literature Review of Real-World Evidence
Nick Jovanoski, Kathleen Bowes, Audrey Brown, Rossella Belleli, Danilo Di Maio, Shkun Chadda, Seye Abogunrin
Lung Cancer Management.2023;[Epub] CrossRef
Conditional survival analysis of patients with resected non–small cell lung cancer
Talib Chaudhry, Vaishnavi Krishnan, Andrew E. Donaldson, Zachary M. Palmisano, Sanjib Basu, Nicole M. Geissen, Justin M. Karush, Gillian C. Alex, Jeffrey A. Borgia, Michael J. Liptay, Christopher W. Seder
JTCVS Open.2023; 16: 948. CrossRef
Clinical Value of Surveillance 18F-fluorodeoxyglucose PET/CT for Detecting Unsuspected Recurrence or Second Primary Cancer in Non-Small Cell Lung Cancer after Curative Therapy
Chae Hong Lim, Soo Bin Park, Hong Kwan Kim, Yong Soo Choi, Jhingook Kim, Yong Chan Ahn, Myung-ju Ahn, Joon Young Choi
Cancers.2022; 14(3): 632. CrossRef
Primary care‐based lung and breast cancer control in China: A commentary on lessons learnt from Korea
Heng Piao, Harry H. X. Wang, Hyejin Lee, Mingyang Yu, Belong Cho
European Journal of Cancer Care.2022;[Epub] CrossRef
Conditional survival nomogram predicting real-time prognosis of locally advanced breast cancer: Analysis of population-based cohort with external validation
Xiangdi Meng, Furong Hao, Zhuojun Ju, Xiaolong Chang, Yinghua Guo
Frontiers in Public Health.2022;[Epub] CrossRef

6,727 View
169 Download
12 Web of Science
13 Crossref

Role of Adjuvant Thoracic Radiation Therapy and Full Dose Chemotherapy in pN2 Non-small Cell Lung Cancer: Elucidation Based on Single Institute Experience: Hyojung Park, Dongryul Oh, Yong Chan Ahn, Hongryull Pyo, Jae Myung Noh, Jong-Mu Sun, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park, Hong Kwan Kim, Yong Soo Choi, Jhingook Kim, Jae Ill Zo, Young Mog Shim; Cancer Res Treat. 2017;49(4):880-889. Published online December 12, 2016; DOI: https://doi.org/10.4143/crt.2016.442

Abstract PDF PubReader ePub

Purpose
The optimal adjuvant therapy modality for treating pN2 non-small cell lung cancer patients has not yet been established. In this study, the authors investigated clinical outcomes following three different adjuvant therapy modalities.
Materials and Methods
From January 2006 to December 2012, 240 patients with cN0/1 disease were found to have pN2 disease following curative resection and received one of three adjuvant therapy modalities:thoracic radiation therapy (TRT) and concurrent chemotherapy (CTx) (CCRT) (group I), CCRT plus consolidation CTx (group II), and CTx alone (group III). TRT was delivered to 155 patients (groups I/II), and full dose CTxwas delivered to 172 patients either as a consolidative or a sole modality (group II/III).
Results
During 30 months of median follow-up, 44 patients died and 141 developed recurrence. The 5-year overall survival (OS), locoregional control (LRC), distant metastasis-free survival (DMFS), and disease-free survival (DFS) rates of all patients were 76.2%, 80.7%, 36.4%, and 29.6%, respectively. There was no difference in OS among groups. TRT (groups I/II) significantly improved LRC, full dose CTx (groups II/III) did DMFS, and CCRT plus consolidation CTx (group II) did DFS, respectively.
Conclusion
The current study could support that TRT could improve LRC and full dose CTx could improve DMFS and that CCRT plus consolidation CTx could improve DFS.

Citations

Citations to this article as recorded by

The effect of adjuvant chemoradiotherapy on survival after R0 resection for stage III-N2 nonsmall cell lung cancer: A meta-analysis
Dailong Li, Wanqiang Li, Yaqi Pang, Lu Xu, Xinhua Xu
Medicine.2022; 101(28): e29580. CrossRef
The efficacy of postoperative radiotherapy for patients with non-small cell lung cancer
Zexu Wang, Baixia Yang, Ping Zhan, Li Wang, Bing Wan
Journal of Cancer Research and Therapeutics.2022; 18(7): 1910. CrossRef

44,147 View
260 Download
3 Web of Science
2 Crossref

A Randomized Phase II Study of Leucovorin/5-Fluorouracil with or without Oxaliplatin (LV5FU2 vs. FOLFOX) for Curatively-Resected, Node-Positive Esophageal Squamous Cell Carcinoma: Sung Hee Lim, Young Mog Shim, Se Hoon Park, Hong Kwan Kim, Young Soo Choi, Myung-Ju Ahn, Keunchil Park, Jae Ill Zo, Jong-Mu Sun; Cancer Res Treat. 2017;49(3):816-823. Published online November 9, 2016; DOI: https://doi.org/10.4143/crt.2016.417

Abstract PDF Supplementary Material PubReader ePub

Purpose
The optimal perioperative treatment for resectable esophageal squamous cell carcinoma (ESCC) remains controversial. We evaluated the efficacy and safety of leucovorin and 5-fluorouracil (LV5FU2) and LV5FU2 plus oxaliplatin (FOLFOX) combination chemotherapies administered adjuvantly for curatively-resected, node-positive ESCC.
Materials and Methods
Patients with pathologically node-positive esophageal cancer after curative R0 resection were enrolled and randomly assigned to receive LV5FU2 or FOLFOX biweekly for up to eight cycles. The primary endpoint was disease-free survival (DFS).
Results
Between 2011 and 2015, 62 patients were randomized into the two treatment groups (32 in the LV5FU2 arm and 30 in the FOLFOX arm). The median age was 60 years and both groups had similar pathologic characteristics in tumor, nodal status, and location. Treatment completion rates were similarly high in both groups. The DFS rate at 12 months was 67% in the LV5FU2 group and 63% in the FOLFOX group with a hazard ratio of 1.3 (95% confidence interval [CI], 0.66 to 2.62). After a median follow-up period of 27 months, the median DFS was 29.6 months (95% CI, 4.9 to 54.2) in the LV5FU2 arm and 16.8 months (95% CI, 7.5 to 26.1) in the FOLFOX arm (p=0.428), respectively, while the median overall survival was not reached in either arm. Grade 3 or 4 neutropenia was more frequent in patients in the FOLFOX arm than the LV5FU2 arm (20.0% vs. 3.1%).
Conclusion
The addition of oxaliplatin (FOLFOX) did not lead to better efficacy compared to LV5FU2 chemotherapy in an adjuvant setting in node-positive ESCC patients.

Citations

Citations to this article as recorded by

Adjuvant chemotherapy in node‐positive patients after esophagectomy for esophageal squamous cell carcinoma
Yeong Jeong Jeon, Jong Ho Cho, Yong Soo Choi, Young Mog Shim, Jong‐Mu Sun, Hong Kwan Kim
Thoracic Cancer.2023; 14(6): 624. CrossRef
Disease-free survival as a surrogate endpoint for overall survival in adults with resectable esophageal or gastroesophageal junction cancer: A correlation meta-analysis
Jaffer A. Ajani, Lisa Leung, Prianka Singh, Murat Kurt, Inkyu Kim, Mir-Masoud Pourrahmat, Steve Kanters
European Journal of Cancer.2022; 170: 119. CrossRef
Substrate-controlled selective acylation of quinazolinones: Access to 2-benzamido-N-formylbenzamides and 3-benzoylquinazolinones
Xianglin Yu, Peng Chen, Ling Jiang, Jun Lin, Yi Jin
Tetrahedron Letters.2022; 103: 153988. CrossRef
Catalyst-free highly regioselective hydrated ring-opening and formylation of quinazolinones
Xianglin Yu, Zhiliang Tang, Kun He, Weina Li, Jun Lin, Yi Jin
Organic & Biomolecular Chemistry.2022; 20(33): 6654. CrossRef
Clinical Trends in Management of Locally Advanced ESCC: Real-World Evidence from a Large Single-Center Cohort Study
Yeong Jeong Jeon, Junsang Yoo, Jong Ho Cho, Young Mog Shim
Cancers.2022; 14(19): 4953. CrossRef
Cardiotoxic effects induced by the use of antimetabolites in the chemotherapy of oncological diseases
Alina A. Aliab'eva, Galina S. Mal
CardioSomatics.2021; 12(3): 177. CrossRef
Antibiotics Improve the Treatment Efficacy of Oxaliplatin-Based but Not Irinotecan-Based Therapy in Advanced Colorectal Cancer Patients
Hiroo Imai, Ken Saijo, Keigo Komine, Yuya Yoshida, Keiju Sasaki, Asako Suzuki, Kota Ouchi, Masahiro Takahashi, Shin Takahashi, Hidekazu Shirota, Masanobu Takahashi, Chikashi Ishioka
Journal of Oncology.2020; 2020: 1. CrossRef
Adjuvant Therapy for Esophageal Squamous Cell Carcinoma
Jong-Mu Sun
The Korean Journal of Thoracic and Cardiovascular Surgery.2020; 53(4): 168. CrossRef
Copper-Catalyzed N-Formylation of Amines through Tandem Amination/Hydrolysis/Decarboxylation Reaction of Ethyl Bromodifluoroacetate
Xiao-Fang Li, Xing-Guo Zhang, Fan Chen, Xiao-Hong Zhang
The Journal of Organic Chemistry.2018; 83(20): 12815. CrossRef
Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer
Vincent T Janmaat, Ewout W Steyerberg, Ate van der Gaast, Ron HJ Mathijssen, Marco J Bruno, Maikel P Peppelenbosch, Ernst J Kuipers, Manon CW Spaander
Cochrane Database of Systematic Reviews.2017;[Epub] CrossRef

10,827 View
272 Download
8 Web of Science
10 Crossref

Clinical Characteristics of Malignant Pericardial Effusion Associated with Recurrence and Survival: Sung-Hwan Kim, Mi Hyang Kwak, Sohee Park, Hak Jin Kim, Hyun-Sung Lee, Moon Soo Kim, Jong Mog Lee, Jae Ill Zo, Jung Sil Ro, Jin Soo Lee; Cancer Res Treat. 2010;42(4):210-216. Published online December 31, 2010; DOI: https://doi.org/10.4143/crt.2010.42.4.210

Abstract PDF PubReader ePub

Purpose

We evaluated clinical outcomes after drainage for malignant pericardial effusion with imminent or overt tamponade.

Materials and Methods

Between August 2001 and June 2007, 100 patients underwent pericardiocentesis for malignant pericardial effusion. Adequate follow-up information on the recurrence of pericardial effusion and survival status was available for 98 patients.

Results

Recurrence of effusion occurred in 30 patients (31%), all of whom were diagnosed with adenocarcinoma. Multivariate analysis indicated that adenocarcinoma of the lung (hazard ratio [HR], 6.6; 95% confidence interval [CI], 1.9 to 22.3; p=0.003) and progressive disease despite chemotherapy (HR, 4.3; 95% CI, 1.6 to 12.0; p=0.005) were independent predictors of recurrence. Survival rates three months after pericardiocentesis differed significantly with the type of primary cancer; the rates were 73%, 18%, 90% and 30% in patients with adenocarcinoma of the lung, squamous cell carcinoma of the lung, breast cancer and other cancers, respectively.

Conclusion

Recurrence and survival of patients with malignant pericardial effusion are dependent on the type of primary cancer and response to chemotherapy. Patients with adenocarcinoma of the lung may be good candidates for surgical drainage to avoid repeated pericardiocentesis, but pericardiocentesis is considered effective as palliative management in patients with other cancers.

Citations

Citations to this article as recorded by

Pericardiocentesis versus window formation in malignant pericardial effusion: trends and outcomes
Jaeoh Lee, Kyu Kim, Seo-Yeon Gwak, Hyun-Jung Lee, Iksung Cho, Geu-Ru Hong, Jong-Won Ha, Chi Young Shim
Heart.2024; 110(12): 863. CrossRef
Pericardial effusion in oncological patients: current knowledge and principles of management
S. Mori, M. Bertamino, L. Guerisoli, S. Stratoti, C. Canale, P Spallarossa, I. Porto, P. Ameri
Cardio-Oncology.2024;[Epub] CrossRef
Malignant Pericardial Effusion: A Systematic Review
Sarah E. Mudra, Danny Rayes, Ashwin K. Kumar, Jason Z. Li, Meredith Njus, Kevin McGowan, Charalampos Charalampous, Kazi A. Kalam, Alveena Syed, Muhammad Majid, Mary Schleicher, Ankit Agrawal, Abdullah Yesilyaprak, Allan L. Klein
CJC Open.2024; 6(8): 967. CrossRef
A Case Report of Video-assisted Thoracoscopic Pericardiectomy for Postpericardiotomy Recurrent Loculated Pericardial Effusion
Hao-Wen Chang, Chen-Liang Tsai
Journal of Medical Sciences.2024; 44(5): 231. CrossRef
Prevalence, characteristics and mortality of cancer patients undergoing pericardiocentesis in the United States between 2004 and 2017
Andrija Matetic, Bonnie Ky, Eric H. Yang, Phyo K. Myint, Muhammad Rashid, Shelley Zieroth, Timir K. Paul, Ayman Elbadawi, Mamas A. Mamas
Cancer Medicine.2023; 12(5): 5471. CrossRef
Breast Cancer Complicated by Cardiac Tamponade in a Patient With Neurofibromatosis Type 1
Narek Hakobyan, Nosakhare Ilerhunmwuwa, Henry O Aiwuyo, Ephrem Sedeta, Ifeanyi Uche, Mustafa Wasifuddin, Jamal C Perry
Cureus.2023;[Epub] CrossRef
Cardiac tamponade
Yehuda Adler, Arsen D. Ristić, Massimo Imazio, Antonio Brucato, Sabine Pankuweit, Ivana Burazor, Petar M. Seferović, Jae K. Oh
Nature Reviews Disease Primers.2023;[Epub] CrossRef
Peritoneal Carcinoma Unveiling a Hidden Threat: A Case of Malignant Pericardial Effusion
Mohammed Abusuliman, Amr M Mohamed, Anas Mahmoud, Tala Beliani, Ibrahim M Ismail-Sayed
Cureus.2023;[Epub] CrossRef
Would the Addition of Immunotherapy Impact the Prognosis of Patients With Malignant Pericardial Effusion?
Varsha Chiruvella, Asad Ullah, Islam Elhelf, Nikhil Patel, Nagla Abdel Karim
Frontiers in Oncology.2022;[Epub] CrossRef
Predictors of Recurrence and Survival in Cancer Patients With Pericardial Effusion Requiring Pericardiocentesis
Talha Ahmed, Elie Mouhayar, Juhee Song, Efstratios Koutroumpakis, Nicolas L. Palaskas, Syed Wamique Yusuf, Juan Lopez-Mattei, Saamir A. Hassan, Peter Kim, Mehmet Cilingiroglu, Konstantinos Marmagkiolis, Ara A. Vaporciyan, Stephen Swisher, Anita Deswal, Ce
Frontiers in Cardiovascular Medicine.2022;[Epub] CrossRef
Malignant Cardiac Tamponade: A Complication of Untreated Breast Cancer
Mohamed Ramzi Almajed, Mark S Obri, Wasih Kamran, Abigail Entz
Cureus.2022;[Epub] CrossRef
High frequency ultrasound‐guided pericardiocentesis performed in the sitting position: A novel apical approach
Lei Zhang, Xue‐Fei Zhang, Zhao Liu, Ying Liu, Cun‐Li Guo, Hua Shao, Bo Li, Cui Zhang, Hui Jing, Wen Cheng
Clinical Cardiology.2021; 44(8): 1106. CrossRef
How to Perform Pericardiocentesis in Cancer Patients With Thrombocytopenia
Robin Jacob, Nicolas L. Palaskas, Juan Lopez-Mattei, Saamir Hassan, Peter Kim, Teodora Donisan, Dinu Valentin Balanescu, Mehmet Cilingiroglu, Konstantinos Marmagkiolis, Cezar Iliescu
JACC: CardioOncology.2021; 3(3): 452. CrossRef
Pericardial Effusion and Cardiac Tamponade: Etiology and Evolution in the Contemporary Era
Claudio Martins de Queiroz, Juliano Cardoso, Felix Ramires, Barbara Ianni, Viviane Tiemi Hotta, Charles Mady, Paula de Cassia Buck, Ricardo Ribeiro Dias, Luciano Nastari, Fábio Fernandes
International Journal of Cardiovascular Sciences.2021; 34(5 Supl 1): 24. CrossRef
The Effect of Lenvatinib in Patients with Thyroid Cancer with Pericardial Metastasis, Which Can Cause Cardiac Tamponade
Keiichiro Okano, Akihito Arai, Satomi Ozawa, Hiroki Morimoto, Gaku Omura, Takahiro Tsujikawa, Shigeru Hirano
Nippon Jibiinkoka Tokeibugeka Gakkai Kaiho(Tokyo).2021; 124(11): 1525. CrossRef
Clinico‐cytopathologic analysis of 574 Pericardial Effusion Specimens: Application of the international system for reporting serous fluid cytopathology (ISRSFC) and long‐term clinical follow‐up
Min Jeong Song, Uiree Jo, Ji‐Seon Jeong, Kyung‐Ja Cho, Gyungyub Gong, Yong Mee Cho, Joon Seon Song
Cancer Medicine.2021; 10(24): 8899. CrossRef
Oncologic Emergencies—The Old, the New, and the Deadly
Krishna Thandra, Zuhair Salah, Sanjay Chawla
Journal of Intensive Care Medicine.2020; 35(1): 3. CrossRef
Acute Myeloid Leukemia Presenting as Effusive Constrictive Pericarditis
Andrew Lutz, Erik B. Schelbert, Konstantinos Lontos, James Rossetti, William Katz
CASE.2020; 4(2): 97. CrossRef
State-of-the-art Review: Interventional Onco-Cardiology
Bala Pushparaji, Konstantinos Marmagkiolis, Cameron K. Miller, Moez K. Aziz, Dinu V. Balanescu, Teodora Donisan, Nicolas Palaskas, Peter Kim, Juan Lopez-Mattei, Mehmet Cilingiroglu, Saamir A. Hassan, Cezar A. Iliescu
Current Treatment Options in Cardiovascular Medicine.2020;[Epub] CrossRef
In vitro cell culture of patient derived malignant pleural and peritoneal effusions for personalised drug screening
Cheng-Guang Wu, Francesca Chiovaro, Alessandra Curioni-Fontecedro, Ruben Casanova, Alex Soltermann
Journal of Translational Medicine.2020;[Epub] CrossRef
Pericardial diseases in patients with cancer: contemporary prevalence, management and outcomes
Massimo Imazio, Marzia Colopi, Gaetano Maria De Ferrari
Heart.2020; 106(8): 569. CrossRef
Update on diagnosis and management of neoplastic pericardial disease
Stefano Avondo, Alessandro Andreis, Matteo Casula, Massimo Imazio
Expert Review of Cardiovascular Therapy.2020; 18(9): 615. CrossRef
Oncological Emergencies from Pathophysiology and Diagnosis to Treatment: A Narrative Review
Ameneh Jafari, Mostafa Rezaei-Tavirani, Maryam Salimi, Reza Tavakkol, Zahra Jafari
Social Work in Public Health.2020; 35(8): 689. CrossRef
Effect of Anti-Inflammatory Drugs on Clinical Outcomes in Patients With Malignant Pericardial Effusion
So Ree Kim, Eun Kyoung Kim, Jinhyun Cho, Sung-A Chang, Sung-Ji Park, Sang-Chol Lee, Seung Woo Park
Journal of the American College of Cardiology.2020; 76(13): 1551. CrossRef
Cancer prevalence, inpatient mortality and its predictors after pericardiocentesis
İ̇dris Buğra ÇERİK, Ferhat DİNDAŞ, Emin KOYUN, İ̇brahim GÜL
Cumhuriyet Medical Journal.2020;[Epub] CrossRef
Neoplastic Pericardial Effusion: A Monocentric Retrospective Study
Elisabetta Di Liso, Alice Menichetti, Maria Vittoria Dieci, Cristina Ghiotto, Alberto Banzato, Alessandra Bianchi, Giovanna Pintacuda, Marta Padovan, Floriana Nappo, Enrico Cumerlato, Federica Miglietta, Eleonora Mioranza, Giulia Zago, Luigi Corti, Valent
Journal of Palliative Medicine.2019; 22(6): 691. CrossRef
Prognostic factors and nomogram for cancer-specific death in non small cell lung cancer with malignant pericardial effusion
Zhi Gang Hu, Ke Hu, Wen Xin Li, Fan Jun Zeng, Anna Halama
PLOS ONE.2019; 14(5): e0217007. CrossRef
Morphological characterization and molecular profiling of malignant pericardial effusion in patients with pulmonary adenocarcinoma
Bing Zhou, Lin Li, Dayou Shi, Tao Jiang, Guohui Xue, Jianping Xiong
Indian Journal of Pathology and Microbiology.2019; 62(4): 566. CrossRef
Cardiac Interventional Procedures in Cardio-Oncology Patients
Teodora Donisan, Dinu Valentin Balanescu, Nicolas Palaskas, Juan Lopez-Mattei, Kaveh Karimzad, Peter Kim, Konstantinos Charitakis, Mehmet Cilingiroglu, Konstantinos Marmagkiolis, Cezar Iliescu
Cardiology Clinics.2019; 37(4): 469. CrossRef
Safety and Outcome of Percutaneous Drainage of Pericardial Effusions in Patients with Cancer
Annop Lekhakul, Chalailak Assawakawintip, Eric R. Fenstad, Sorin V. Pislaru, Jeremy J. Thaden, Larry J. Sinak, Garvan C. Kane
The American Journal of Cardiology.2018; 122(6): 1091. CrossRef
The value of the new scoring system for predicting neoplastic pericarditis in the patients with large pericardial effusion
M. Szturmowicz, A. Pawlak-Cieślik, A. Fijałkowska, J. Gątarek, A. Skoczylas, M. Dybowska, K. Błasińska-Przerwa, R. Langfort, W. Tomkowski
Supportive Care in Cancer.2017; 25(8): 2399. CrossRef
Cardiovascular Complications of Cancer Therapy
Hui-Ming Chang, Tochukwu M. Okwuosa, Tiziano Scarabelli, Rohit Moudgil, Edward T.H. Yeh
Journal of the American College of Cardiology.2017; 70(20): 2552. CrossRef
Pericarditis as a Marker of Occult Cancer and a Prognostic Factor for Cancer Mortality
Kirstine Kobberøe Søgaard, Dóra Körmendiné Farkas, Vera Ehrenstein, Krishnan Bhaskaran, Hans Erik Bøtker, Henrik Toft Sørensen
Circulation.2017; 136(11): 996. CrossRef
A Minimum Volume of More Than 60 mL Is Necessary for Adequate Cytologic Diagnosis of Malignant Pericardial Effusions
Lisa M. Rooper, Syed Z. Ali, Matthew T. Olson
American Journal of Clinical Pathology.2016; 145(1): 101. CrossRef
Patient with Small Cell Lung Carcinoma and Suspected Right Upper Lobe Abscess Presenting with a Purulent Pericardial Effusion
Khushboo Goel, Huthayfa Ateeli, Neil M. Ampel, Dena L’heureux
American Journal of Case Reports.2016; 17: 523. CrossRef
Surgical pericardial drainage in a series of 235 consecutive patients: an 8-year experience
Ali Azari, Negar Manavifar, Veda Vakili, Leila Bigdelu
Indian Journal of Thoracic and Cardiovascular Surgery.2016; 32(4): 250. CrossRef
2015 update on the diagnosis and management of neoplastic pericardial disease
Chiara Lestuzzi, Massimiliano Berretta, Witold Tomkowski
Expert Review of Cardiovascular Therapy.2015; 13(4): 377. CrossRef
Outcomes of Cancer Patients Undergoing Percutaneous Pericardiocentesis for Pericardial Effusion
Danielle El Haddad, Cezar Iliescu, Syed Wamique Yusuf, William Nassib William, Tarif H. Khair, Juhee Song, Elie N. Mouhayar
Journal of the American College of Cardiology.2015; 66(10): 1119. CrossRef
Haemodynamic Monitoring of Pericardial Effusion with Cardiac Tamponade in a Patient with Colorectal Cancer

Journal of Anesthesia & Critical Care: Open Access.2015;[Epub] CrossRef
Un traitement local ambitieux est-il envisageable en cas de métastases intrapéricardiques d’un cancer bronchique ?
M. Riquet, C. Rivera, P. Mordant, É. Fabre
Revue des Maladies Respiratoires.2014; 31(5): 439. CrossRef
Les autres métastases
A. Roche, C. Audigier-Valette
Revue des Maladies Respiratoires Actualités.2014; 6(2): 173. CrossRef
Análisis de las características clínicas, ecocardiográficas, microbiológicas y citopatológicas de derrames pericárdicos en un hospital de tercer nivel de atención
José Martín Santa Cruz-Ruiz, Guillermo Sahagún-Sánchez, Diana González-Cabello, Nydia Sánchez-González
Archivos de Cardiología de México.2014; 84(2): 86. CrossRef
Infiltrative Cardiomyopathy and Pericardial Disease
Syed Wamique Yusuf, Smita I. Negi, Daniel J. Lenihan
Seminars in Oncology.2013; 40(2): 199. CrossRef
Malignant Pericardial Effusion
I. Burazor, M. Imazio, G. Markel, Y. Adler
Cardiology.2013; 124(4): 224. CrossRef
Prognostic relevance of pericardial effusion in patients with malignant diseases
Tae-Dong Jeong, Seongsoo Jang, Chan-Jeoung Park, Hyun-Sook Chi
The Korean Journal of Hematology.2012; 47(3): 237. CrossRef
Surgical properties and survival of a pericardial window via left minithoracotomy for benign and malignant pericardial tamponade in cancer patients
Sezai Celik, Muharrem Celik, Bulent Aydemir, Handan Tanrıkulu, Tamer Okay, Nurşen Tanrikulu
World Journal of Surgical Oncology.2012;[Epub] CrossRef
Pericardial Diseases
David M. Dudzinski, Gary S. Mak, Judy W. Hung
Current Problems in Cardiology.2012; 37(3): 75. CrossRef
Epidemiology, diagnosis and therapy of neoplastic pericarditis
Chiara Lestuzzi
Journal of Cardiovascular Echography.2011; 21(2): 86. CrossRef
Oncologic emergencies: Pathophysiology, presentation, diagnosis, and treatment
Mark A. Lewis, Andrea Wahner Hendrickson, Timothy J. Moynihan
CA: A Cancer Journal for Clinicians.2011; 61(5): 287. CrossRef

11,993 View
94 Download
49 Crossref

FDG-PET in Mediastinal Nodal Staging of Non-small Cell Lung Cancer: Correlation of False Results with Histopathologic Finding: Hee Jong Baek, Jin Haeng Chung, Jong Ho Park, Jae Ill Zo, Gi Jeong Cheon, Chang Woon Choi, Sang Moo Lim, Soo Yong Choi, Jong Myeon Hong, Jang Soo Hong; Cancer Res Treat. 2003;35(3):232-238. Published online June 30, 2003; DOI: https://doi.org/10.4143/crt.2003.35.3.232

Abstract PDF

PURPOSE
Mediastinal staging of non-small cell lung cancer can be markedly improved by FDG-PET scan, but the problem of false staging of mediastinal nodes by PET scan in non-small cell lung cancer has not yet been overcome. The aim of this study was to identify the mechanism underlying the false staging of mediastinal nodes by FDG-PET in the case of non-small cell lung cancer. MATERIALS AND METHODS: To evaluate the factors determining the FDG uptake in mediastinal nodes, FDG-PET was performed preoperatively, and mediastinal dissection with pulmonary resection was performed in 62 patients with NSCLC. GLUT-1 expression was studied by immunohistochemistry of the mediastinal nodes (n=111, true positive 31, true negative 41, false positive 27, false negative 12) using the anti-GLUT-1 antibody. The size, percentage of tumor (tumor ratio), labeling index (rate of stained tumor), staining intensity of the tumor, level of follicular hyperplasia, and staining intensity of the follicle center in the mediastinal node were also studied. RESULTS: There was no significant difference in size among the 4 nodal groups (TP, TN, FP, FN), nor in the tumor ratio of the metastatic nodes between the TP and FN groups. The labeling index and staining intensity of the TP group were higher than those of the FN group (Mann-Whitney test, p=.001, p=.007) in the case of the metastatic nodes. The level of follicular hyperplasia of the FP group was higher than that of the TN group in the case of the non-metastatic nodes (p=.000). CONCLUSION: These results suggest that in mediastinal staging of non-small cell lung cancer by FDG-PET, the FN node is associated with low uptake of FDG due to low expression of GLUT-1, and that the FP node is associated with a high level of follicular hyperplasia as a result of there being a reactive change to an inflammatory and/or immune reaction. This is the first report on the mechanism underlying the false results that are sometimes obtained, and which constitute a major problem in the clinical application of FDG-PET to the mediastinal staging of non-small cell lung cancer.

Citations

Citations to this article as recorded by

Value of glucose transport protein 1 expression in detecting lymph node metastasis in patients with colorectal cancer
Hongsik Kim, Song-Yi Choi, Tae-Young Heo, Kyeong-Rok Kim, Jisun Lee, Min Young Yoo, Taek-Gu Lee, Joung-Ho Han
World Journal of Clinical Cases.2024; 12(5): 931. CrossRef
Associations between GLUT expression and SUV values derived from FDG-PET in different tumors—A systematic review and meta analysis
Hans-Jonas Meyer, Andreas Wienke, Alexey Surov, Pankaj K Singh
PLOS ONE.2019; 14(6): e0217781. CrossRef

3,825 View
22 Download
2 Crossref

Clinico-pathologic Study on Multiple Squamous Epithelial Neoplasia of the Esophagus: Kyung Ja Cho, Seung Sook Lee, Jae Soo Koh, Jae Ill Zo, Ja June Jang; J Korean Cancer Assoc. 1999;31(3):598-606.

Abstract PDF: PURPOSE
Multicentric occurrence of esophageal squamous neoplasm has been known to be significant in terms of its pathogenesis and production of detectable early lesions. This study was performed to establish the incidence, pattem and clinico-pathologic features of multiple squamous epithelial neoplasia of the esophagus in Korea.
MATERIALS AND METHODS
Forty-two consecutive cases of esophageal squamous cell carcinoma surgically treated at Korea Cancer Center Hospital in 1991 were studied. For pathological analysis, whole esophagectomy specimens were sectioned, micrascopically examined, and reconstructed. Age, sex, alcohol and smoking history, tumor location, stage, lymph node metastasis and survival were compared among different neoplastic conditions.
RESULT
Fifteen cases (35.7%) showed multiple squamous lesions, 6 (14.3%) with multiple carcinomas and dysplasias, and 9 (21.4%) with single carcinomas with separate dysplasias. Intraepithelial lesions contiguous to main tumors were commonly observed (61.9%). Lugol`s solution staining pattern was compatible with epithelial pathology. Lymph node metastasis rate was significantly higher in cases with multiple carcinomas. Smoking history was significantly more common in patients with solitary catcinomas only.
CONCLUSION
The multicentric occurrence of squamous epithelial dysplasia and carcinoma in the esophagus was confirmed in Korean patients, supporting the concept of field carcinogenesis at this region. However, lack of evidence for strong environmental influence in the patients with multiple lesions suggests yet another risk factor.

2,304 View
12 Download

Accuracy of Properative Pathologic Diagnosis and Clinical Staging for Clinically Staged 3A Non - Small Cell Lung Cancer: Mi Sook Kim, Kyoung Hwan Koh, Seong Yul Yoo, Chul Koo Cho, Jae Ill Zo, Young Soo Do, Kyung Ja Cho; J Korean Cancer Assoc. 1995;27(5):816-822.

Abstract PDF: The clinical staging of lung cancer, especially stage IIIA, provides important information for clinical analysis and treatment method to surgeon ar radiation oncologist. The aim of this analysis is to evaluate of difference between clinical staging and pathologic staging and determine to accuracy of preoperative pathologic diagnosis and clinical staging for clinically staged IIIA NSCLC. Analysis was performed on 138 patients who has been staged IIIA NSCLC. Pathologic diagnosis was performed using sputum cytology, bronchoscopy or percutaneous needle aspiration. All patients were evaluated by CT and staged according to American Joint Commit- tee on Cancer staging classification. All patients received the thoracotomy. The pathologic diagnosis was changed after surgery in 9 patients(6.5%). The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of CT in dis- tinguishing T3 from Tl-T2 were 62.5%, 89.7%, 47.6%, 87.5%, and 75.3%, respectively. The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of CT in distinguishing N2 from NO-Nl were 91.8%, 24.3%, 42.7%, 78.3%, and 54.8% respec- tively. According to pathologic staging, there were 27(19.6%) patients in stage I, 24(17.4%) in stage II, 64(46.4%) in stage IIIA, 21(15.2%) in stage IIIB, and 2(1.5%) in stage IV. Comparing clincal staging with pathologic staging, concordant results were found in 46.4%, 37.0% were clinically overestimated and 16.7% underestimated. Preoperative pathologic diagnosis was well correlate postoperative pathologic finding. But CT accuracy was low in both primary tumor and mediastinal lymph node. Especially to diagnose malignant involvement of mediastinal nodes, CT is not a valid means. Patients would not be denied the opportunity for curative surgery on the basis of CT signs.

2,617 View
14 Download

Pathologic Observatiosn and P-glycoprotein Expression in Esophageal Carcinomas Treated with Preoperative chemotherapy: Chang Won Ha, Kyung Ja Cho, Young Mog Shim, Jae Ill Zo, Ja June Jang; J Korean Cancer Assoc. 1994;26(4):529-534.

Abstract PDF: Neoadjuvant chemotherpay of esophageal cancers is recently considered to be beneficial to downstaging of tumors. This study was aimed ta describe morphologic alterations and expression of P-glycoprotein in esophageal cancers after chemotherapy and discuse their clinical sig- nificances. Eleven cases of esophageal cancers which were surgicelly resected l-5 cycles of chemotherapy with C-DDP/VP-16/5-FU(PEF)or C-DDP/5-FU(FP) were reviewed. On microscopic examination, all of ll cases(100%) revealed no major pathologic alterations. Only five cases(45%) showed non-specific partial pathologic responses, histologically observing foreign body reaction, calcification, necrosis, desmoplasia, vascular dilatation, and nuclear anaplasia. The changes were also observed in metastatic tumors in regional lymph nodes. The presence of non-specific pathologic responses and downstaging of tumors did not correlate each other. Immunohistochemically, all of the cases were negative for P-glycoprotein. Our data suggest that PEF or FP neoadjuvant chemotherpay for esophageal cancers is ineffecitive.

2,446 View
16 Download

Mutation of K - ras Oncogene in Non - Small Cell lung Cancer: Choon Taek Lee, Keun Chil Park, Chang Min Kim, Jae Ill Zo, Young Mog Shim, Weon Seon Hong, Jhin Oh Lee, Taik Koo Yun; J Korean Cancer Assoc. 1994;26(1):100-106.

Abstract PDF: The mutations of K-ras oncogenes have been detected in about 20~30% of non-small cell lung cancer(NSCLC). In some reports K-ras activations are associated with smoking and poor prognosis in NSCLC patients who undergo curative resection. The ras oncogenes are usually activated by point mutations. The development of polymerase chain reaction-single strand conformation polymorphism(PCR-SSCP) enables us to detect the subtle nucleotide changes such as point mutations. In SSCP the electrophoretic mobility of single strand nucleotide de- pends on not only its size but also its conformation determined by DNA sequences. We analysed genomic DNAs of 41 human NSCLC obtained by thoracotomy using PCR-SSCP of K- ras codon 12, 13 and K-ras codon 61, and compared the results with clinical informations. The electrophoretic mobility changes were found in 10 of 41 NSCLCs(24.4%) in K-ras codon 12, 13. Those changes were found in six of 25 squamous cell carcinomas(24% ) and four of 16 adenocarcinomas(25%). But no change was found in K-ras codon 61. Comparisans of clinical parameters including age, sex, stage, smoking, and survival showedno significant differences between two groups with or without K-ras mutation. These results suggest that the mutation of K-ras oncogene may play an important role in the pathogenesis of some group of NSCLC though the clinical significances of these molecular events are open to further investigations.

2,632 View
23 Download

Author index